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For Protein Misassembly, Minireview
It’s the “I” Decade
Ronald Wetzel aggregation in vitro and in bacteria during folding and
1732 Hamilton Drive unfolding suggested that these processes, in fact, could
Phoenixville, Pennsylvania 19460 involve specific interactions of folding intermediates
(Mitraki and King, 1989). For example, David Brems and
colleagues at Upjohn showed that a folding intermediate
Insoluble aggregates of normally well-behaved proteins is involved in the aggregation of growth hormone in vitro
are featured in a variety of human disease states, includ- and that the hydrophobic face of a particular helix is
ing various forms of amyloidosis (Sipe, 1992) and the important to this interaction. The Jonathan King group
prion diseases (Prusiner and DeArmond, 1995). Protein at MIT identified a series of temperature sensitive folding
aggregation and precipitation is also a commonplace mutations that function not by destabilizing the protein’s
observation in biotechnology, in both the inclusion body native state butby placing a particular folding intermedi-
formation that can occur in the cell during heterologous ate in jeopardy, leading to the irreversible formation of
expression of cDNAs and in attempts to refold these inclusion bodies.
proteins in vitro (Mitraki and King, 1989). In addition, it In this article I review the highlights of work over the
is now well-accepted that a primary function of many past few years that provides further support of misas-
molecular chaperones is to thwart misassembly and ag- sembly mechanisms involving structured folding inter-
gregation during the protein folding process (Hartl, mediates, especially with respect to human diseases
1996). There is a voluminous literature on the interaction involving protein deposition. Many of these studies also
of chaperones with proteins in various states of folding. begin to address key questions suggested by the
There has been generally less interest in the character- involvement of partially folded states: structural details
ization of aggregation processes or products in non- on the aggregation intermediates and the aggregates
chaperoned folding, perhaps in part because of histori- themselves, specificity of aggregate formation, and
cal assumptions about the nature of the phenomenon. strategies for inhibiting these processes.
The conventional wisdom regarding protein aggrega- Conformational Changes in Protein
tion and precipitation has occupied two extreme posi- Misassembly In Vivo
tions. Some processes, like aggregation during folding In principle, the formation of aggregate from a folding
of a protein in vitro, or inclusion body formation in bacte- intermediate can take place either in the folding or un-
ria, are usually regarded as being driven by nonspecific, folding direction (Figure 2, top). Interestingly, both path-
hydrophobic interactions operating on random coil ways areprobably represented in cases of protein depo-
states or on collapsed, molten globule states. Other sition in vivo (Wetzel, 1992). In the case of cytoplasmic
processes, such as the extracellular aggregation of inclusion body formation in bacteria, off-pathway aggre-
some proteins into amyloid fibrils, have been visualized gation probably most often occurs in the folding direc-
according to the sickle hemoglobin model, in which mu-
tion, with the extent of deposition depending on a kinetic
tations alter the local surface properties of the native,
competition between productive folding and aggrega-
folded state to introduce new packing interactions for
tion for a poorly soluble, transient intermediate. Amyloid
noncovalent polymerization. The first view tends to dis-
formation, in which fibrils are deposited outside the cell,courage attempts at mechanistic understanding and
presumably occurs at some point after proteins havetherapeutic intervention; the second suggests that the
had an opportunity to complete most or all of the foldingstraightforward route to both lies in the determination
process. In this case, aggregate formation seems toof the high resolution structures of native states.
involve unfolding intermediates that can be populated,Folding Intermediates and Protein Misassembly
in equilibrium with the native state, under physiologicalRecent results suggest, however, that many examples
conditions. The in vitro correlate for the former processof protein aggregation occur by mechanisms involving
is the lossof molecules due to aggregationduring refold-structured folding intermediates. There are several im-
ing of denatured proteins; the correlate for the latterportant implications of such mechanisms. One is that
is the loss of molecules to aggregation during thermalthere exists a class of diseases involving aberrant pro-
unfolding of native proteins.tein folding. Another is that such processes can involve
Amyloid fibril formation associated with different hu-interactions that exhibit significant structural specificity
man disease states occurs with a variety of differentwhich cannot be deduced by the examination of native
proteins and peptides that have no obvious commonstates.
properties in amino acid sequence, three-dimensionalThis is not a new idea. In 1974, Michel Goldberg and
structure, or function (Sipe, 1992). Despite these differ-colleagues put forward a model for the unfolding-
ences, amyloid fibrils are remarkably similar in size andinduced aggregation of multidomain proteins in vitro
shape as viewed in the electron microscope, and also(Mitraki and King, 1989). This model, shown in Figure 1,
share dye-binding and optical properties that suggestinvokes structured folding intermediates with domains
significant structural similarity (Sipe, 1992). There is nowor subdomains folded as they are in the native state,
substantial evidence that unfolding intermediates arebut which undergo intermolecular, rather than intramo-
the building blocks for amyloid fibril formation from glob-lecular, interactions with each other during folding or
ular proteins. For example, the kinetics of amyloid fibrilunfolding—leading to the formation of polymers of par-
formation in vitro by the wild type version of the proteintially folded states held together by noncovalent, native-
like interactions. In the 1980s a few studies on protein transthyretin are most favorable under conditions in
Cell
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Figure 1. Models for Structurally Specific
Aggregation of Partially Folded States
Native globular proteins (N) exposed to dena-
turing stress might generate partially folded
states containing domains which retain sig-
nificant native-like structure (Inat). These do-
mains could noncovalently aggregate inter-
molecularly by utilizing some of the same
packing interactions that exist intramolecu-
larly in the native state. Alternatively, partially
folded intermediates could form in which
some sequences rearrange to non-native
structural elements (Inon) that mediate the for-
mation of aggregates via packing by non-
native interactions.
which the protein is in a non-native state (Kelly, 1996). form contains more b-sheet (Prusiner and DeArmond,
1995). These results suggest that some protein misas-Furthermore, amyloid disease-associated mutations in
transthyretin (Kelly, 1996) and immunoglobulin light sembly processes may require significant secondary
structural rearrangements for oligomerization to pro-chain VL domain (Helms and Wetzel, 1996) have been
shown to destabilize the native states of these proteins, ceed (Figure 1).
Structure of the Aggregated Stateallowing them to more easily enter global, cooperative
unfolding transitions that can generate partially folded One of the major challenges in this field is to move
beyond these initial observations by determining at highstates that are the presumptive amyloidogenic interme-
diates. resolution the structures of both bona fide aggregation
intermediates and of final aggregated states. There areThe involvement of non-native states in amyloid for-
mation is also supported by data suggesting that the significant technical barriers to achieving this, however.
For example, the metastable nature and inherently poorsecondary structural content of the protein in the aggre-
gated state is different from the native state. For exam- solubilities of aggregation-prone folding intermediates
make solution-phase NMR analysis difficult. For the ag-ple, the fundamental structural unit of all amyloid fibrils
is thought to be stacked, anti-parallel b-sheet (Sipe, gregates themselves, new solid state NMR methods are
being developed which may ultimately provide impor-1992), but some amyloid-forming proteins, such as apo-
lipoprotein A-1, are rich in a-helix in the native state. tant distance constraints to support construction of
models of amyloid structure (Lansbury et al., 1995).Similarly, the cellular form of the prion protein is rich in
a-helix when isolated, while the aggregated, infectious In the solid state, aggregates like amyloid fibrils are,
Figure 2. Models for Folding and Aggre-
gation
For a globular protein with a significant free
energy of stabilization (top), the aggregation-
prone folding intermediate I can be formed
during the folding of the unfolded state U to
the folded state N, or in the unfolding of N to
U. At least in the case of some small amy-
loidogenic peptides (bottom), self-associa-
tion of the aggregation-prone conformation
A will be unfavorable until aggregate size is
sufficiently large to provide a “nucleus” C
possessing a degree of internal stability. Ac-
cording to this mechanism, aggregation can
also be initiated when a small amount of ag-
gregate is provided exogenously, to “seed”
fibril formation. The mechanism shown for
globular protein folding is illustrative and is
not intended to be comprehensive with re-
spect to possible protein folding pathways;
for example, in some cases the aggregation-
prone folding intermediate might exist on a
shunt off the productive folding pathway. Neither are the mechanisms shown on the top and bottom halves of this Figure mutually exclusive;
thus, the aggregation pathway for some peptides may also contain prerequisite conformational changes (B→A), and for globular proteins
may require formation of a multimeric nucleus.
The numbered steps of the mechanism refer to some points where aggregation can be inhibited, as discussed in the text.
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at best, paracrystalline, and thus cannot be solved at discerning test of relatedness—at the molecular level—
high resolution by conventional X-ray crystallographic may be the ability of an aggregate to provide a growth
methods. However, recent synchrotron X-ray studies of point, or seed, for further aggregation. A nucleated
aligned fibrils have provided sufficient data to support growth mechanism (Figure 2, bottom) has been demon-
construction of a model for an amyloid fibril. This impor- strated for several amyloid peptides in vitro (Jarrett and
tant model features a continuous b-sheet helix, and Lansbury, 1993). One peptide that exhibits nucleation
strongly suggests the involvement of a non-native sub- and seeding in fibril formation is the Alzheimer’s peptide
unit in fibril formation (Blake and Serpell, 1996). Ab. This peptide forms amyloid fibrils when incubated
Despite their limitations in direct analysis of aggrega- at pH 7.4, but more amorphous aggregates when incu-
tion intermediates and the aggregated state, conven- bated at pH 5.8 (Wood et al., 1996c). Although these
tional X-ray crystallography and solution NMR analysis two aggregate types are composed of exactly the same
do have important roles to play in this field. For example, peptide, the pH 5.8 aggregate—in contrast to the pH 7.4
the high-resolution structures of a number of unusual aggregate—is incapable of seeding Ab fibril formation at
“domain-swapped” dimeric proteins have been de- pH 7.4.
scribed (Bennett et al., 1995) which clearly support the Inhibition of Protein Misassembly
Goldberg model of oligomerization by native-like inter- If disease-related protein aggregation is mediated by
actions of folding intermediates (Figure 1). High resolu- precise packing interactions of structurally well-defined
tion structures of an aggregating protein’s native state partially folded intermediates, it becomes more feasible
also can provide valuable clues to the aggregation pro- to consider the possibility of interfering with these inter-
cess. The recently described structure of a major frag- actions by the traditional pharmaceutical approach of
ment of the prion protein (Riek et al., 1996) identified the identifying small molecules which bind to and block
locations of the expected a-helices and also unveiled a interaction sites. Some possible points of attack are
small element of b-sheet structure which may turn out indicated in Figure 2. Stabilization of the native state of
to be involved in the aggregation process. Refined transthyretin by ligand-binding (1) has been reported to
X-ray crystal structures and NMR solution structures stabilize the protein against fibril formation invitro (Miroy
can also give valuable information on the most mobile— et al., 1996). Small organic molecules can inhibit the off-
and thus perhaps most labile—elements of the folded pathway aggregation of proteins during folding in vitro
structure, in turn suggesting where unfolding might start (Rudolph, 1996), probably by discouraging aggregate
and what an early unfolding intermediate might look like. packing (2). In vitro fibril formation by Ab can also be
Multiple Aggregated States inhibited by small molecules (Wood et al., 1996b), which
There are now several examples in which similar or iden- apparently bind to Ab and in doing so either interfere
tical proteins are capable of forming different aggregate with self-association (4) or shift a conformational equilib-
types, as assessed by morphological or functional crite- rium of the monomer away from the amyloidogenic form
ria. This has several important implications. In particular, (3). Nucleation (Evans et al., 1995) and seeding (Wood
if the biological effects of protein deposition in some et al., 1996a) of Ab fibril formation (5) can be inhibited
human diseases are attributable to the specific interac- in vitro by apolipoprotein E, which may help to explain
tions of the aggregate with particular molecules or cells, the genetic risk for developing Alzheimer’s disease as-
then different aggregated forms of the same protein may sociated with certain apoE alleles.Noncovalent associa-
have different pathological consequences. Thus, the tion of proteins into aggregates can set the stage for
ability to form aggregates of functionally different mor- several modes of covalent crosslinking, which would be
phologies may help explain how themisfolding ormisas- expected to make reversal in vivo much more difficult.
sembly of a single prion protein sequence can give rise
Agents capable of selectively breaking these covalent
to various scrapie “strains” (Kocisko et al., 1995). In fact,
crosslinks (Vasan et al., 1996) might play an important
infectious prions are known to exhibit morphologically
role in the therapeutic disaggregation of such aggre-
distinct aggregated states, although the exact relation-
gates.ship between any of these states and the neurotoxic
It is well known that amino acid sequence controlsand infectious properties of prions is not clear (Prusiner
the final form a protein takes when it folds, and theand DeArmond, 1995).
free energy by which that native state is favored. OnlyIn another example, aggregates of immunoglobulin
recently has it become apparent that amino acid se-variable domains are involved in both light chain amy-
quence also controls the viability of the path(s) to theloidosis (AL) and light chain deposition disease (LCDD),
correct structure, by controlling and limiting the degreebut the morphology of the deposited aggregates are
to which misassembly and aggregation irreversibly si-clearly different. Not only are both AL and LCDD asso-
phon protein molecules from the folding pathway. It isciated with destabilizing amino acid changes, but the
now clear that these side reactions of folding are notnature of these sequence changes may also help dic-
only of fundamental interest for the rules for correcttate aggregate morphology and hence disease type
translation of genetic information into functional pro-(Helms and Wetzel, 1996). One way particular sequence
teins, they also control the features of a growing bodychanges might control aggregate morphology is by con-
of pathological protein deposition phenomena. At pres-trolling the extent to which different aggregation-prone
ent we can only make out the rough features of this newunfolding intermediates (such as Inat and Inon in Figure 1)
landscape—the structural biology of non-native states.are populated under physiological conditions.
It may be necessary to devise new tools to bring it toAlthough aggregate morphology informs us about
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